Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Receivables (2017 - 2019)

Cogent Biosciences' Receivables history spans 3 years, with the latest figure at $2.0 million for Q4 2019.

  • Quarterly Receivables rose 19.9% to $2.0 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2019, up 19.9% year-over-year, with the annual reading at $2.0 million for FY2019, 19.9% up from the prior year.
  • Receivables came in at $2.0 million for Q4 2019, up from $880000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.0 million in Q1 2019 to a low of $830000.0 in Q4 2017.
  • The 3-year median for Receivables is $1.5 million (2019), against an average of $1.5 million.
  • Year-over-year, Receivables soared 100.96% in 2018 and then plummeted 37.98% in 2019.
  • Cogent Biosciences' Receivables stood at $830000.0 in 2017, then skyrocketed by 100.96% to $1.7 million in 2018, then rose by 19.9% to $2.0 million in 2019.
  • Per Business Quant, the three most recent readings for COGT's Receivables are $2.0 million (Q4 2019), $880000.0 (Q3 2019), and $1.5 million (Q2 2019).